Cancer gene decoded
Nature Immunology
August 26, 2013
The pathway which B immune cell lymphomas can arise is presented in a study published online this week in Nature Immunology. The findings identify MEF2B protein as a potential target for treatment of certain B cell lymphomas.
Diffuse large B cell lymphomas (DLBCLs) represent a common form of non-Hodgkin’s cancer of the blood. A substantial fraction of DLBCLs arise from mutations of either the BCL6 or MEF2B genes, although the connection between the two genes was previously unclear.
Riccardo Dalla-Favera and colleagues show MEF2B encodes a transcription factor that activates expression of BCL6. MEF2B protein activity is itself tightly regulated. Mutations that relieve the inhibitory regulation of BCL6 expression or MEF2B protein activity enhance the potential of activated B cells to undergo cancerous transformation. The authors show that inhibiting MEF2B function could block proliferation of DLBCL cell lines, indicating its potential as a therapeutic target.
doi: 10.1038/ni.2688
Research highlights
-
Dec 4
Archaeology: Palaeolithic sea voyage to Japanese islands beyond the horizonScientific Reports
-
Dec 3
Ageing: Cellular rejuvenation restores vision in miceNature
-
Dec 1
Neurodegenerative disease: Two blood molecules may predict Alzheimer’s disease developmentNature Aging
-
Nov 27
Archaeology: Neanderthal thumbs better adapted to holding tools with handlesScientific Reports
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 26
Metabolism: Link between SARS-CoV-2 infection and cholesterol hints at COVID-19 treatment possibilitiesNature Metabolism
